

**CORTEVA, INC.**  
**QUARTERLY SUPPLEMENTAL FINANCIAL DATA AND NON-GAAP RECONCILIATIONS**  
**(UNAUDITED)**  
**March 31, 2026**

<u>INDEX</u>	<u>PAGE</u>
SELECTED INCOME STATEMENT DATA	2
SEGMENT INFORMATION	3
SIGNIFICANT ITEMS	4
RECONCILIATION OF NON-GAAP MEASURES	5 - 7

**Non-GAAP Financial Measures:** This presentation includes information that does not conform to U.S. Generally Accepted Accounting Principles ("GAAP") and are considered non-GAAP measures. These measures include operating EBITDA, operating EBITDA margin, operating earnings, operating earnings (loss) per share, Free Cash Flow, and Free Cash Flow Conversion. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided on pages 5 through 7.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures, except for Free Cash Flow, to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company's control, such as significant items, without unreasonable effort. For significant items reported in the periods presented, refer to the significant items details included within. Beginning January 1, 2020, the company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the noncash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. Due to the ramp-up of Enlist E3™, Corteva significantly reduced the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform thereafter. In 2023 and 2024, the company committed to restructuring activities to optimize the Crop Protection network of manufacturing and external partners, which are expected to be substantially complete in 2026. The company expects to record approximately \$80 million to \$90 million net pre-tax restructuring charges during 2026 for these activities.

Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites and the 2021 officer indemnification payment. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales. Operating earnings (loss) and operating earnings (loss) per share are defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of separation costs, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Corteva Separation from DowDuPont and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

The Company also uses Free Cash Flow and Free Cash Flow Conversion as non-GAAP measures to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures. Free Cash Flow Conversion is defined as Free Cash Flow divided by Operating EBITDA. Management believes that Free Cash Flow and Free Cash Flow Conversion provides investors with meaningful information regarding the Company's ongoing ability to generate cash through core operations, and the Company's ability to service its indebtedness, pay dividends (when declared), make share repurchases, and meet its ongoing cash needs for its operations. Corteva is not able to reconcile its forward-looking Free Cash Flow Conversion non-GAAP financial measure to its most comparable U.S. GAAP financial measure, as it is unable to predict with reasonable certainty Operating EBITDA due to items outside of the Company's control, which include the same significant items noted above, without unreasonable effort.

**SELECTED INCOME STATEMENT DATA (UNAUDITED)**  
(dollars in millions, except per share)

	Year to Date						Year					Year					Year				
	1Q26	2025	4Q25	3Q25	2Q25	1Q25	2024	4Q24	3Q24	2Q24	1Q24	2023	4Q23	3Q23	2Q23	1Q23	2022	4Q22	3Q22	2Q22	1Q22
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported
<b>Consolidated Net Sales (GAAP)</b>	\$ 4,905	\$ 17,401	\$ 3,910	\$ 2,618	\$ 6,456	\$ 4,417	\$ 16,908	\$ 3,978	\$ 2,326	\$ 6,112	\$ 4,492	\$ 17,226	\$ 3,707	\$ 2,590	\$ 6,045	\$ 4,884	\$ 17,455	\$ 3,825	\$ 2,777	\$ 6,252	\$ 4,601
<b>Income (Loss) from Continuing Operations Attributable to Corteva Common Stockholders, After Tax (GAAP)</b>	\$ 722	\$ 1,193	\$ (540)	\$ (310)	\$ 1,380	\$ 663	\$ 851	\$ (52)	\$ (522)	\$ 1,053	\$ 372	\$ 929	\$ (233)	\$ (318)	\$ 877	\$ 603	\$ 1,205	\$ (43)	\$ (325)	\$ 999	\$ 574
<b>Non-Operating Benefits (Costs), After Tax <sup>(1)</sup></b>	\$ (1)	\$ (36)	\$ (8)	\$ (12)	\$ (8)	\$ (8)	\$ (127)	\$ (29)	\$ (37)	\$ (21)	\$ (40)	\$ (111)	\$ (27)	\$ (16)	\$ (35)	\$ (33)	\$ 80	\$ (16)	\$ 4	\$ 43	\$ 49
<b>Amortization of Intangibles (Existing as of Corteva Separation), After Tax <sup>(1)</sup></b>	\$ (106)	\$ (434)	\$ (107)	\$ (108)	\$ (110)	\$ (109)	\$ (459)	\$ (109)	\$ (115)	\$ (118)	\$ (117)	\$ (471)	\$ (117)	\$ (118)	\$ (118)	\$ (118)	\$ (542)	\$ (128)	\$ (137)	\$ (138)	\$ (139)
<b>Mark-to-market Gains (Losses) on Certain Foreign Currency Contracts not Designated as Hedges, After Tax <sup>(1)(3)</sup></b>	\$ (3)	\$ —	\$ 44	\$ (4)	\$ (33)	\$ (7)	\$ —	\$ (3)	\$ (11)	\$ 15	\$ (1)	\$ —	\$ 25	\$ 34	\$ (48)	\$ (11)	\$ —	\$ (2)	\$ 4	\$ 26	\$ (28)
<b>Significant Items Benefit (Charge), After Tax <sup>(1)</sup></b>	\$ (135)	\$ (582)	\$ (596)	\$ (23)	\$ 27	\$ 10	\$ (351)	\$ (132)	\$ (21)	\$ (103)	\$ (95)	\$ (403)	\$ (217)	\$ (57)	\$ (61)	\$ (68)	\$ (267)	\$ (14)	\$ (110)	\$ (127)	\$ (16)
<b>Separation Costs, After Tax <sup>(1)</sup></b>	\$ (42)	\$ (31)	\$ (24)	\$ (7)	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
<b>Operating Earnings (Loss) (Non-GAAP) <sup>(1)</sup></b>	\$ 1,009	\$ 2,276	\$ 151	\$ (156)	\$ 1,504	\$ 777	\$ 1,788	\$ 221	\$ (338)	\$ 1,280	\$ 625	\$ 1,914	\$ 103	\$ (161)	\$ 1,139	\$ 833	\$ 1,934	\$ 117	\$ (86)	\$ 1,195	\$ 708
<b>Earnings (Loss) Per Share - Diluted (GAAP) <sup>(2)</sup></b>	\$ 1.07	\$ 1.75	\$ (0.80)	\$ (0.46)	\$ 2.02	\$ 0.97	\$ 1.22	\$ (0.08)	\$ (0.76)	\$ 1.51	\$ 0.53	\$ 1.30	\$ (0.33)	\$ (0.45)	\$ 1.23	\$ 0.84	\$ 1.66	\$ (0.06)	\$ (0.45)	\$ 1.37	\$ 0.79
<b>Operating Earnings (Loss) Per Share (Non-GAAP) <sup>(1)(2)</sup></b>	\$ 1.50	\$ 3.34	\$ 0.22	\$ (0.23)	\$ 2.20	\$ 1.13	\$ 2.57	\$ 0.32	\$ (0.49)	\$ 1.83	\$ 0.89	\$ 2.69	\$ 0.15	\$ (0.23)	\$ 1.60	\$ 1.16	\$ 2.67	\$ 0.16	\$ (0.12)	\$ 1.64	\$ 0.97
<b>Diluted Shares Outstanding (millions)</b>	673.6	681.4	674.7	678.7	683.1	686.6	696.0	687.3	691.1	698.1	702.8	711.9	704.0	708.4	713.7	716.2	724.5	714.7	718.7	726.7	730.9
<b>Cash Provided by (used for) Operating Activities - Continuing Operations (GAAP)</b>	\$	\$ 3,457				\$	\$ 2,296				\$	\$ 1,809			\$	\$ 912					
<b>Free Cash Flow (Non-GAAP) <sup>(1)</sup></b>	\$	\$ 2,866				\$	\$ 1,699				\$	\$ 1,214			\$	\$ 307					

(1) See Reconciliation of Non-GAAP Measures on pages 5 to 7.

(2) Earnings (loss) per share and operating earnings (loss) per share for the year may not equal the sum of quarterly earnings per share due to rounding.

(3) Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting.

**SEGMENT NET SALES (UNAUDITED)**  
(dollars in millions)

SEGMENT NET SALES	Year						Year					Year					Year				
	1Q26	2025	4Q25	3Q25	2Q25	1Q25	2024	4Q24	3Q24	2Q24	1Q24	2023	4Q23	3Q23	2Q23	1Q23	2022	4Q22	3Q22	2Q22	1Q22
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported
Seed	\$ 3,023	\$ 9,898	\$ 1,737	\$ 917	\$ 4,537	\$ 2,707	\$ 9,545	\$ 1,772	\$ 691	\$ 4,331	\$ 2,751	\$ 9,472	\$ 1,635	\$ 878	\$ 4,264	\$ 2,695	\$ 8,979	\$ 1,646	\$ 862	\$ 3,947	\$ 2,524
Crop Protection	1,882	7,503	2,173	1,701	1,919	1,710	7,363	2,206	1,635	1,781	1,741	7,754	2,072	1,712	1,781	2,189	8,476	2,179	1,915	2,305	2,077
<b>CONSOLIDATED NET SALES</b>	<b>\$ 4,905</b>	<b>\$ 17,401</b>	<b>\$ 3,910</b>	<b>\$ 2,618</b>	<b>\$ 6,456</b>	<b>\$ 4,417</b>	<b>\$ 16,908</b>	<b>\$ 3,978</b>	<b>\$ 2,326</b>	<b>\$ 6,112</b>	<b>\$ 4,492</b>	<b>\$ 17,226</b>	<b>\$ 3,707</b>	<b>\$ 2,590</b>	<b>\$ 6,045</b>	<b>\$ 4,884</b>	<b>\$ 17,455</b>	<b>\$ 3,825</b>	<b>\$ 2,777</b>	<b>\$ 6,252</b>	<b>\$ 4,601</b>

**OPERATING EBITDA (UNAUDITED)**  
(dollars in millions)

OPERATING EBITDA	Year						Year					Year					Year				
	1Q26	2025	4Q25	3Q25	2Q25	1Q25	2024	4Q24	3Q24	2Q24	1Q24	2023	4Q23	3Q23	2Q23	1Q23	2022	4Q22	3Q22	2Q22	1Q22
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported
Seed	\$ 1,034	\$ 2,636	\$ 124	\$ (193)	\$ 1,863	\$ 842	\$ 2,219	\$ 93	\$ (320)	\$ 1,698	\$ 748	\$ 2,117	\$ 145	\$ (138)	\$ 1,458	\$ 652	\$ 1,656	\$ 71	\$ (224)	\$ 1,240	\$ 569
Crop Protection	434	1,350	360	279	334	377	1,272	461	246	255	310	1,374	267	184	320	603	1,684	332	352	509	491
Corporate Expenses	(30)	(138)	(38)	(37)	(33)	(30)	(115)	(29)	26	(36)	(24)	(110)	(26)	(28)	(32)	(24)	(116)	(33)	(32)	(30)	(21)
<b>CORTEVA OPERATING EBITDA (Non-GAAP) <sup>(1)</sup></b>	<b>\$ 1,438</b>	<b>\$ 3,848</b>	<b>\$ 446</b>	<b>\$ 49</b>	<b>\$ 2,164</b>	<b>\$ 1,189</b>	<b>\$ 3,376</b>	<b>\$ 525</b>	<b>\$ (100)</b>	<b>\$ 1,917</b>	<b>\$ 1,034</b>	<b>\$ 3,381</b>	<b>\$ 386</b>	<b>\$ 18</b>	<b>\$ 1,746</b>	<b>\$ 1,231</b>	<b>\$ 3,224</b>	<b>\$ 370</b>	<b>\$ 96</b>	<b>\$ 1,719</b>	<b>\$ 1,039</b>

(1) See Reconciliation of Non-GAAP Measures on page 5.

**SEGMENT OPERATING EBITDA MARGIN % AND CORTEVA OPERATING EBITDA MARGIN % (UNAUDITED)**

SEGMENT OPERATING EBITDA MARGIN %	Year						Year					Year					Year				
	1Q26	2025	4Q25	3Q25	2Q25	1Q25	2024	4Q24	3Q24	2Q24	1Q24	2023	4Q23	3Q23	2Q23	1Q23	2022	4Q22	3Q22	2Q22	1Q22
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported
Seed	34.2 %	26.6 %	7.1 %	(21.0)%	41.1 %	31.1 %	23.2 %	5.2 %	(46.3)%	39.2 %	27.2 %	22.4 %	8.9 %	(15.7)%	34.2 %	24.2 %	18.4 %	4.3 %	(26.0)%	31.4 %	22.5 %
Crop Protection	23.1 %	18.0 %	16.6 %	16.4 %	17.4 %	22.0 %	17.3 %	20.9 %	15.0 %	14.3 %	17.8 %	17.7 %	12.9 %	10.7 %	18.0 %	27.5 %	19.9 %	15.2 %	18.4 %	22.1 %	23.6 %
<b>TOTAL OPERATING EBITDA MARGIN % (Non-GAAP) <sup>(2)</sup></b>	<b>29.3 %</b>	<b>22.1 %</b>	<b>11.4 %</b>	<b>1.9 %</b>	<b>33.5 %</b>	<b>26.9 %</b>	<b>20.0 %</b>	<b>13.2 %</b>	<b>(4.3)%</b>	<b>31.4 %</b>	<b>23.0 %</b>	<b>19.6 %</b>	<b>10.4 %</b>	<b>0.7 %</b>	<b>28.9 %</b>	<b>25.2 %</b>	<b>18.5 %</b>	<b>9.7 %</b>	<b>3.5 %</b>	<b>27.5 %</b>	<b>22.6 %</b>

(2) Operating EBITDA margin %s for Corporate are not presented separately above as they are not meaningful; however, the results are included in the Total Operating EBITDA Margin %s above.

**SIGNIFICANT ITEMS (UNAUDITED)**  
(dollars in millions)

SIGNIFICANT ITEMS	Year						Year					Year					Year				
	1Q26	2025	4Q25	3Q25	2Q25	1Q25	2024	4Q24	3Q24	2Q24	1Q24	2023	4Q23	3Q23	2Q23	1Q23	2022	4Q22	3Q22	2Q22	1Q22
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported
Restructuring and asset related charges - net	\$ (92)	\$ (146)	\$ (15)	\$ (30)	\$ (79)	\$ (22)	\$ (288)	\$ (89)	\$ (32)	\$ (92)	\$ (75)	\$ (336)	\$ (241)	\$ (2)	\$ (60)	\$ (33)	\$ (363)	\$ (63)	\$ (152)	\$ (143)	\$ (5)
Employee Retention Credit <sup>(1)</sup>	—	—	—	—	—	—	—	—	—	—	—	3	—	—	3	—	9	—	9	—	—
Bayer resolution <sup>(1) (3)</sup>	—	(610)	(610)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Estimated settlement expense <sup>(1) (5)</sup>	—	—	—	—	—	—	(101)	—	—	(47)	(54)	(204)	(48)	(66)	(41)	(49)	(87)	(30)	(40)	—	(17)
Litigation settlement <sup>(1) (4)</sup>	(85)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Inventory write-offs <sup>(2) (6)</sup>	—	—	—	—	—	—	2	—	—	2	—	(7)	—	—	(3)	(4)	(33)	—	(32)	(1)	—
Spare parts write-offs <sup>(2) (7)</sup>	—	—	—	—	—	—	—	—	—	—	—	(12)	(12)	—	—	—	—	—	—	—	—
Settlement costs associated with Russia Exit <sup>(1) (6)</sup>	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	(8)	—	(2)	(6)	—
Gain (loss) on sale of business, assets and equity investments <sup>(1) (6) (7)</sup>	—	37	23	—	14	—	7	—	—	3	4	14	7	4	—	3	10	—	15	(5)	—
AltEn facility remediation charge <sup>(2) (9)</sup>	—	(37)	—	—	—	(37)	—	—	—	—	—	(10)	(10)	—	—	—	(33)	(33)	—	—	—
Seed sale associated with Russia Exit <sup>(6) (8)</sup>	—	—	—	—	—	—	—	—	—	—	—	18	—	—	(1)	19	3	3	—	—	—
Acquisition-related costs <sup>(10)</sup>	—	—	—	—	—	—	(6)	—	(1)	(3)	(2)	(45)	(4)	(7)	(15)	(19)	—	—	—	—	—
Insurance proceeds <sup>(11)</sup>	—	98	—	—	98	—	71	71	—	—	—	—	—	—	—	—	—	—	—	—	—
<b>TOTAL PRE-TAX SIGNIFICANT ITEMS BENEFIT (CHARGE) <sup>(14)</sup></b>	<b>\$ (177)</b>	<b>\$ (658)</b>	<b>\$ (602)</b>	<b>\$ (30)</b>	<b>\$ 33</b>	<b>\$ (59)</b>	<b>\$ (315)</b>	<b>\$ (18)</b>	<b>\$ (33)</b>	<b>\$ (137)</b>	<b>\$ (127)</b>	<b>\$ (579)</b>	<b>\$ (308)</b>	<b>\$ (71)</b>	<b>\$ (117)</b>	<b>\$ (83)</b>	<b>\$ (502)</b>	<b>\$ (123)</b>	<b>\$ (202)</b>	<b>\$ (155)</b>	<b>\$ (22)</b>
+Total tax (provision) benefit impact of significant items <sup>(12)</sup>	42	153	138	7	(6)	14	80	6	8	34	32	131	75	14	27	15	102	31	37	28	6
+Tax only significant item benefit (charge) <sup>(13)</sup>	—	(77)	(132)	—	—	55	(116)	(120)	4	—	—	45	16	—	29	—	133	78	55	—	—
<b>TOTAL SIGNIFICANT ITEMS BENEFIT (CHARGE), AFTER TAX <sup>(15)</sup></b>	<b>\$ (135)</b>	<b>\$ (582)</b>	<b>\$ (596)</b>	<b>\$ (23)</b>	<b>\$ 27</b>	<b>\$ 10</b>	<b>\$ (351)</b>	<b>\$ (132)</b>	<b>\$ (21)</b>	<b>\$ (103)</b>	<b>\$ (95)</b>	<b>\$ (403)</b>	<b>\$ (217)</b>	<b>\$ (57)</b>	<b>\$ (61)</b>	<b>\$ (68)</b>	<b>\$ (267)</b>	<b>\$ (14)</b>	<b>\$ (110)</b>	<b>\$ (127)</b>	<b>\$ (16)</b>

(1) Included in other income (expense) - net.

(2) Included in cost of goods sold.

(3) Consists of a charge relating to the resolution of litigation with Bayer.

(4) Consists of a settlement charge associated with the Crop Protection loyalty program multi-district litigation plaintiffs.

(5) Includes a charge for estimated Lorsban® related charges.

(6) The gain (loss) on sale of business, assets and equity investments recognized in the second quarter 2025, as well as in 2024, 2023 and 2022, are associated with activities related to the 2022 Restructuring Actions. The inventory write-offs, settlement costs associated with Russia Exit and seed sale associated with Russia exit recognized in 2023 and 2022 are also associated with activities related to the 2022 Restructuring Actions. The second quarter 2024 includes a \$2 benefit associated with sales of inventory previously reserved for in association with the 2022 Restructuring Actions.

(7) The gain (loss) on sale of business, assets and equity investments recognized in the fourth quarter 2025 and the spare parts write-offs recognized in 2023 are associated with activities related to the Crop Protection Operations Strategy Restructuring Program.

(8) Second and first quarter 2023 and the fourth quarter 2022 includes a benefit (charge) of \$(1), \$19 and \$3, respectively, relating to the sale of seeds already under production in Russia when the decision to exit the country was made and that the Company was contractually required to purchase. The second and first quarter 2023 and the fourth quarter 2022 consisted of \$30, \$41 and \$8, respectively, of net sales and \$31, \$22 and \$5, respectively, of cost of goods sold.

(9) This charge relates to the increase in the remediation accrual at the AltEn facility relating to Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans.

(10) This charge relates to transaction and third-party integration costs associated with the completed acquisitions of Stoller and Symborg as well as the recognition of the inventory fair value step-up, which is included in selling, general and administrative expenses and cost of goods sold, respectively.

(11) Includes proceeds received related to prior significant items.

(12) The income tax effect for each significant item was calculated based on the statutory tax rate for the jurisdiction(s) in which the significant item was taxable or deductible.

(13) Primarily related to a deferred tax benefit associated with a change in a legal entity's U.S. tax characterization, the establishment of a tax valuation allowance against the individual net deferred tax asset positions of the Brazil Seed legal entity and Brazil Crop Protection legal entity, the impact of deferred taxes and a tax currency change for legal entities within Switzerland, adjustments due to intellectual property realignment, a worthless stock deduction in the U.S., a change in a U.S. legal entity's tax characterization resulting in the establishment of deferred taxes, and the release of a tax valuation allowance recorded against the net deferred tax asset position of a Brazil legal entity.

(14) Impact on income (loss) from continuing operations before income taxes.

(15) Impact on income (loss) from continuing operations after income taxes.

**RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)**  
(dollars in millions)

RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS AFTER INCOME TAXES TO OPERATING EBITDA	1Q26	Year 2025					Year 2024					Year 2023					Year 2022				
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	
<b>Income (loss) from continuing operations after income taxes (GAAP)</b>	\$ 725	\$ 1,204	\$ (537)	\$ (308)	\$ 1,382	\$ 667	\$ 863	\$ (50)	\$ (519)	\$ 1,056	\$ 376	\$ 941	\$ (231)	\$ (315)	\$ 880	\$ 607	\$ 1,216	\$ (41)	\$ (322)	\$ 1,002	\$ 577
Provision for (benefit from) income taxes on continuing operations	133	484	7	(62)	422	117	412	138	(114)	282	106	152	(92)	(129)	204	169	210	(162)	(74)	325	121
<b>Income (loss) from continuing operations before income taxes (GAAP)</b>	\$ 858	\$ 1,688	\$ (530)	\$ (370)	\$ 1,804	\$ 784	\$ 1,275	\$ 88	\$ (633)	\$ 1,338	\$ 482	\$ 1,093	\$ (323)	\$ (444)	\$ 1,084	\$ 776	\$ 1,426	\$ (203)	\$ (396)	\$ 1,327	\$ 698
Depreciation and amortization	297	1,203	306	300	301	296	1,227	302	306	312	307	1,211	312	306	306	287	1,223	304	310	302	307
Interest income	(34)	(136)	(44)	(29)	(31)	(32)	(132)	(39)	(33)	(25)	(35)	(283)	(130)	(59)	(54)	(40)	(124)	(49)	(36)	(24)	(15)
Interest expense	36	180	46	46	52	36	233	60	66	66	41	233	62	58	82	31	79	36	18	16	9
Exchange (gains) losses - net	67	181	84	45	25	27	284	50	97	78	59	397	155	102	104	36	229	133	13	36	47
Non-operating (benefits) costs - net	(18)	39	12	14	3	10	174	42	50	30	52	151	36	28	44	43	(111)	23	(9)	(60)	(65)
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges <sup>(1)</sup>	3	—	(58)	6	43	9	—	4	14	(19)	1	—	(34)	(44)	63	15	—	3	(6)	(33)	36
Significant items (benefit) charge	177	658	602	30	(33)	59	315	18	33	137	127	579	308	71	117	83	502	123	202	155	22
Separation costs	52	35	28	7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
<b>Operating EBITDA (Non-GAAP)</b>	\$ 1,438	\$ 3,848	\$ 446	\$ 49	\$ 2,164	\$ 1,189	\$ 3,376	\$ 525	\$ (100)	\$ 1,917	\$ 1,034	\$ 3,381	\$ 386	\$ 18	\$ 1,746	\$ 1,231	\$ 3,224	\$ 370	\$ 96	\$ 1,719	\$ 1,039

(1) Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting.

**RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)**  
(dollars in millions, except per share)

	1Q26	Year 2025					Year 2024					Year 2023					Year 2022				
	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	As Reported	
<b>OPERATING EARNINGS (LOSS) (Non-GAAP)</b>																					
Income (Loss) from Continuing Operations Attributable to Corteva Common Stockholders (GAAP)	\$ 722	\$ 1,193	\$ (540)	\$ (310)	\$ 1,380	\$ 663	\$ 851	\$ (52)	\$ (522)	\$ 1,053	\$ 372	\$ 929	\$ (233)	\$ (318)	\$ 877	\$ 603	\$ 1,205	\$ (43)	\$ (325)	\$ 999	\$ 574
Less: Non-operating benefits (costs), after tax <sup>(1)</sup>	(1)	(36)	(8)	(12)	(8)	(8)	(127)	(29)	(37)	(21)	(40)	(111)	(27)	(16)	(35)	(33)	80	(16)	4	43	49
Less: Amortization of intangibles (existing as of Corteva Separation), after tax <sup>(1)</sup>	(106)	(434)	(107)	(108)	(110)	(109)	(459)	(109)	(115)	(118)	(117)	(471)	(117)	(118)	(118)	(118)	(542)	(128)	(137)	(138)	(139)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax <sup>(1)(4)</sup>	(3)	—	44	(4)	(33)	(7)	—	(3)	(11)	15	(1)	-	25	34	(48)	(11)	-	(2)	4	26	(28)
Less: Significant items benefit (charge), after tax <sup>(1)</sup>	(135)	(582)	(596)	(23)	27	10	(351)	(132)	(21)	(103)	(95)	(403)	(217)	(57)	(61)	(68)	(267)	(14)	(110)	(127)	(16)
Less: Separation costs, after tax <sup>(1)</sup>	(42)	(31)	(24)	(7)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
<b>Operating Earnings (Loss) (Non-GAAP)</b>	<b>\$ 1,009</b>	<b>\$ 2,276</b>	<b>\$ 151</b>	<b>\$ (156)</b>	<b>\$ 1,504</b>	<b>\$ 777</b>	<b>\$ 1,788</b>	<b>\$ 221</b>	<b>\$ (338)</b>	<b>\$ 1,280</b>	<b>\$ 625</b>	<b>\$ 1,914</b>	<b>\$ 103</b>	<b>\$ (161)</b>	<b>\$ 1,139</b>	<b>\$ 833</b>	<b>\$ 1,934</b>	<b>\$ 117</b>	<b>\$ (86)</b>	<b>\$ 1,195</b>	<b>\$ 708</b>
<b>OPERATING EARNINGS (LOSS) PER SHARE (Non-GAAP)</b>																					
Earnings (Loss) Per Share of Common Stock from Continuing Operations Attributable to Corteva Common Stockholders - Diluted (GAAP)	\$ 1.07	\$ 1.75	\$ (0.80)	\$ (0.46)	\$ 2.02	\$ 0.97	\$ 1.22	\$ (0.08)	\$ (0.76)	\$ 1.51	\$ 0.53	\$ 1.30	\$ (0.33)	\$ (0.45)	\$ 1.23	\$ 0.84	\$ 1.66	\$ (0.06)	\$ (0.45)	\$ 1.37	\$ 0.79
Less: Non-operating benefits (costs), after tax <sup>(2)</sup>	—	(0.05)	(0.01)	(0.02)	(0.01)	(0.01)	(0.18)	(0.04)	(0.05)	(0.03)	(0.06)	(0.16)	(0.04)	(0.02)	(0.04)	(0.05)	0.11	(0.02)	-	0.06	0.07
Less: Amortization of intangibles (existing as of Corteva Separation), after tax <sup>(2)</sup>	(0.16)	(0.64)	(0.16)	(0.16)	(0.16)	(0.16)	(0.67)	(0.16)	(0.17)	(0.16)	(0.17)	(0.66)	(0.17)	(0.17)	(0.17)	(0.16)	(0.75)	(0.18)	(0.19)	(0.19)	(0.19)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax <sup>(2)(4)</sup>	(0.01)	—	0.07	(0.01)	(0.05)	(0.01)	—	(0.01)	(0.02)	0.02	-	-	0.04	0.05	(0.07)	(0.02)	-	-	0.01	0.04	(0.04)
Less: Significant items benefit (charge), after tax <sup>(2)</sup>	(0.20)	(0.85)	(0.88)	(0.03)	0.04	0.02	(0.50)	(0.19)	(0.03)	(0.15)	(0.13)	(0.57)	(0.31)	(0.08)	(0.09)	(0.09)	(0.37)	(0.02)	(0.15)	(0.18)	(0.02)
Less: Separation costs, after tax <sup>(2)</sup>	(0.06)	(0.05)	(0.04)	(0.01)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
<b>Operating Earnings (Loss) Per Share (Non-GAAP)<sup>(3)</sup></b>	<b>\$ 1.50</b>	<b>\$ 3.34</b>	<b>\$ 0.22</b>	<b>\$ (0.23)</b>	<b>\$ 2.20</b>	<b>\$ 1.13</b>	<b>\$ 2.57</b>	<b>\$ 0.32</b>	<b>\$ (0.49)</b>	<b>\$ 1.83</b>	<b>\$ 0.89</b>	<b>\$ 2.69</b>	<b>\$ 0.15</b>	<b>\$ (0.23)</b>	<b>\$ 1.60</b>	<b>\$ 1.16</b>	<b>\$ 2.67</b>	<b>\$ 0.16</b>	<b>\$ (0.12)</b>	<b>\$ 1.64</b>	<b>\$ 0.97</b>

(1) Impact on net income (loss) from continuing operations available to Corteva common stockholders. The income tax effect for each adjustment was calculated based on the statutory tax rate for the jurisdiction(s) in which the adjustment was taxable or deductible (unless otherwise disclosed on page 4).

(2) Impact on earnings (loss) per common share - diluted. The income tax effect for each adjustment was calculated based on the statutory tax rate for the jurisdiction(s) in which the adjustment was taxable or deductible (unless otherwise disclosed on page 4).

(3) Operating earnings (loss) per share for the year may not equal the sum of quarterly operating earnings per share due to rounding.

(4) Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting.

**RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)**  
(dollars in millions)

<i>\$ In millions</i>	Year 2025	Year 2024	Year 2023
<b>Cash provided by (used for) operating activities - continuing operations (GAAP)</b>	\$ 3,457	\$ 2,296	\$ 1,809
Less: Capital expenditures	(591)	(597)	(595)
<b>Free Cash Flow (Non-GAAP) <sup>1</sup></b>	\$ 2,866	\$ 1,699	\$ 1,214
<b>Corteva Operating EBITDA (Non-GAAP) <sup>2</sup></b>	\$ 3,848	\$ 3,376	\$ 3,381
<b>Free Cash Flow Conversion (Non-GAAP) <sup>3</sup></b>	74 %	50 %	36 %
<p>1. Free Cash Flow is defined as cash provided by (used for) operating activities - continuing operations, less capital expenditures.</p> <p>2. Refer to the "Non-GAAP Calculation of Corteva Operating EBITDA" reconciliation for further discussion on Operating EBITDA.</p> <p>3. Free Cash Flow Conversion represents Free Cash Flow divided by Operating EBITDA.</p>			